Matches in SemOpenAlex for { <https://semopenalex.org/work/W1606946093> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W1606946093 endingPage "5" @default.
- W1606946093 startingPage "5471" @default.
- W1606946093 abstract "Antibodies reactive with human epidermal growth factor receptor (EGFr), such as 225 IgG1 (Masui et al., Cancer Res., 44: 1002-1007, 1984), are effective tumor-suppressive agents in xenograft models. In the present study an additional antibody reactive with EGFr was made and compared to 225 IgG1 for antitumor activity as an unmodified antibody or as a drug immunoconjugate. This IgG1 clone, designated EGFrL11, competed with EGF and immunoprecipitated a Mr 178,000 protein identical to that immunoprecipitated with 225 IgG1. Cross-competition and immunodepletion studies indicated that the two antibodies bound to distinct epitopes on the same molecule. Immunofluorescence studies confirmed that the EGFrL11 epitope was expressed on the surface of viable human squamous cell carcinoma lines including T222. Unmodified EGFrL11 and 225 IgG1 were tested for antitumor activity in T222 xenografts. At a dose of 81 mg/kg given twice weekly for 3 weeks, tumor suppression, but not regression, occurred with EGFrL11. A similar result was obtained with 225 IgG1. To gauge the potential of these antibodies as immunoconjugates, both were tested for antitumor activity in the T222 model after conjugation to the Vinca derivative 4-desacetylvinblastine-3-carboxhydrazide. Both immunoconjugates completely regressed established tumors. These data suggest that Vinca conjugates with EGFr-reactive monoclonal antibodies warrant further investigation as possible clinical candidates." @default.
- W1606946093 created "2016-06-24" @default.
- W1606946093 creator A5050854363 @default.
- W1606946093 creator A5060357627 @default.
- W1606946093 creator A5079817381 @default.
- W1606946093 date "1991-10-15" @default.
- W1606946093 modified "2023-09-23" @default.
- W1606946093 title "Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates." @default.
- W1606946093 cites W1481887457 @default.
- W1606946093 cites W1556931607 @default.
- W1606946093 cites W1975579612 @default.
- W1606946093 cites W2014095906 @default.
- W1606946093 cites W2030522563 @default.
- W1606946093 cites W2043306817 @default.
- W1606946093 cites W2056780782 @default.
- W1606946093 cites W2062985891 @default.
- W1606946093 cites W2070283605 @default.
- W1606946093 cites W2093498921 @default.
- W1606946093 cites W2100837269 @default.
- W1606946093 cites W2110439220 @default.
- W1606946093 cites W2117642675 @default.
- W1606946093 cites W2121808641 @default.
- W1606946093 cites W2148508657 @default.
- W1606946093 cites W2237040806 @default.
- W1606946093 cites W2271639847 @default.
- W1606946093 cites W2316765704 @default.
- W1606946093 cites W1570334509 @default.
- W1606946093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1913667" @default.
- W1606946093 hasPublicationYear "1991" @default.
- W1606946093 type Work @default.
- W1606946093 sameAs 1606946093 @default.
- W1606946093 citedByCount "7" @default.
- W1606946093 countsByYear W16069460932016 @default.
- W1606946093 crossrefType "journal-article" @default.
- W1606946093 hasAuthorship W1606946093A5050854363 @default.
- W1606946093 hasAuthorship W1606946093A5060357627 @default.
- W1606946093 hasAuthorship W1606946093A5079817381 @default.
- W1606946093 hasConcept C153911025 @default.
- W1606946093 hasConcept C159654299 @default.
- W1606946093 hasConcept C170493617 @default.
- W1606946093 hasConcept C185592680 @default.
- W1606946093 hasConcept C195616568 @default.
- W1606946093 hasConcept C203014093 @default.
- W1606946093 hasConcept C2776362946 @default.
- W1606946093 hasConcept C2777096885 @default.
- W1606946093 hasConcept C2778556491 @default.
- W1606946093 hasConcept C2779438470 @default.
- W1606946093 hasConcept C502942594 @default.
- W1606946093 hasConcept C542903549 @default.
- W1606946093 hasConcept C55493867 @default.
- W1606946093 hasConcept C86803240 @default.
- W1606946093 hasConcept C98274493 @default.
- W1606946093 hasConceptScore W1606946093C153911025 @default.
- W1606946093 hasConceptScore W1606946093C159654299 @default.
- W1606946093 hasConceptScore W1606946093C170493617 @default.
- W1606946093 hasConceptScore W1606946093C185592680 @default.
- W1606946093 hasConceptScore W1606946093C195616568 @default.
- W1606946093 hasConceptScore W1606946093C203014093 @default.
- W1606946093 hasConceptScore W1606946093C2776362946 @default.
- W1606946093 hasConceptScore W1606946093C2777096885 @default.
- W1606946093 hasConceptScore W1606946093C2778556491 @default.
- W1606946093 hasConceptScore W1606946093C2779438470 @default.
- W1606946093 hasConceptScore W1606946093C502942594 @default.
- W1606946093 hasConceptScore W1606946093C542903549 @default.
- W1606946093 hasConceptScore W1606946093C55493867 @default.
- W1606946093 hasConceptScore W1606946093C86803240 @default.
- W1606946093 hasConceptScore W1606946093C98274493 @default.
- W1606946093 hasIssue "20" @default.
- W1606946093 hasLocation W16069460931 @default.
- W1606946093 hasOpenAccess W1606946093 @default.
- W1606946093 hasPrimaryLocation W16069460931 @default.
- W1606946093 hasRelatedWork W1591820460 @default.
- W1606946093 hasRelatedWork W16592107 @default.
- W1606946093 hasRelatedWork W1987801792 @default.
- W1606946093 hasRelatedWork W1988955679 @default.
- W1606946093 hasRelatedWork W2009889818 @default.
- W1606946093 hasRelatedWork W2021033071 @default.
- W1606946093 hasRelatedWork W2112311127 @default.
- W1606946093 hasRelatedWork W2188879094 @default.
- W1606946093 hasRelatedWork W2356338171 @default.
- W1606946093 hasRelatedWork W2420962063 @default.
- W1606946093 hasVolume "51" @default.
- W1606946093 isParatext "false" @default.
- W1606946093 isRetracted "false" @default.
- W1606946093 magId "1606946093" @default.
- W1606946093 workType "article" @default.